Bleeding rates in patients with congenital hemophilia B without inhibitors: A systematic review and meta-analysis
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-6613
Abstract: INTRODUCTION: Hemophilia B is a rare, X-linked disorder caused by F9 gene mutations, leading to deficient or dysfunctional clotting factor IX and bleeding complications. Emerging therapies including extended half-life products, non-factor therapies, and gene therapies… read more here.
Keywords: abr; meta analysis; patients years; included patients ... See more keywords
A breakthrough in treatment of cancer patients with grade 4/profound febrile neutropenia.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.15_suppl.e14513
Abstract: e14513 Background: febrile neutropenia (FN) remains one of the most serious side effects of chemotherapy treatment, which is life-threatening. Late consequence of FN is dose reduction and delaying of therapies. Actual guidelines allows granulocyte-colony-stimulating factors… read more here.
Keywords: chemotherapy; profound febrile; treatment; included patients ... See more keywords